Roivant Sciences (ROIV) Business Segments — Gain on litigation settlement — Quarterly & Annual

Screener

Similar metrics at other companies

DKSDICK’S — Litigation Settlement, Gain

$150M—

TDCGain on settlement

$0—

TDCGain on litigation settlement

$0—

UISGain on litigation settlement

$10M—

TXGGain on litigation settlement

$0-100%

BKNGReportable Segment — Gain related to settlement of litigation matters

$89M—

Other financials

Income statement

Revenue$1.4M-33.5%

Operating income-$366.0M-28.5%

Net income-$189.8M+15.0%

EPS (diluted)-$0.26+21.2%

Balance sheet

Cash & equivalents$77.1M-18.7%

Total debt$107.2M+7.5%

Total equity$4.2B-2.6%

Total assets$5.3B+5.4%

Cash flow

Operating cash flow-$270.5M-32.4%

CapEx$419.0K-89.6%

Free cash flow-$270.9M-30.0%

Valuation

Market cap$25B+214%

Enterprise value$25.03B+215%

P/S3,318.5×+2,976×

Profitability

Operating margin-9,130.5%-13,995pp

Net margin-6,079.9%-6,193pp

FCF margin-10,901%-22,382pp

Returns & leverage

Return on equity-17.1%-17.7pp

Debt / equity0×0.0×

Current ratio16.7×-23.8×

Where this comes from

Reported directly by Roivant Sciences in its filing.

Tagged under the XBRL concept us-gaap:LitigationSettlementGain.

The source filing: Roivant Sciences’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 7:28 AM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q2 2026
Accession: 0001635088-26-000090

Line item	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025
Research and development (includes $8,721 and $11,099 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively)	202,016	152,919
General and administrative (includes $74,621 and $71,079 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively)	165,527	134,019
Total operating expenses	367,827	287,092
Gain on litigation settlement	392	—
Loss from operations	(365,993)	(284,922)
Change in fair value of investments	(36,637)	19,125
Change in fair value of liability instruments	—	2,329
Interest income	(36,922)	(48,322)

Item 1. Financial Statements (Unaudited).

FAQ

What is Roivant Sciences's business segments — gain on litigation settlement?: Roivant Sciences (ROIV) reported business segments — gain on litigation settlement of $392K in Q2 2026.
What does business segments — gain on litigation settlement mean?: This represents non-recurring income recognized from the successful resolution of legal disputes or patent litigation. It reflects the financial recovery from claims against third parties related to intellectual property or contractual breaches. Such gains are typically excluded from core operating performance due to their non-operational and infrequent nature.

Ask your AI about Roivant Sciences's business segments — gain on litigation settlement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk